Notable Reporting: What Will Happen to Signal Genetics Inc Next? The Stock Just Increased A Lot

Notable Reporting: What Will Happen to Signal Genetics Inc Next? The Stock Just Increased A Lot

The stock of Signal Genetics Inc (NASDAQ:SGNL) is a huge mover today! About 141,338 shares traded hands or 1203.25% up from the average. Signal Genetics Inc (NASDAQ:SGNL) has declined 57.16% since April 7, 2016 and is downtrending. It has underperformed by 61.95% the S&P500.
The move comes after 5 months positive chart setup for the $46.28 million company. It was reported on Nov, 9 by Barchart.com. We have $13.56 PT which if reached, will make NASDAQ:SGNL worth $84.69 million more.

Signal Genetics Inc (NASDAQ:SGNL) Ratings Coverage

Out of 3 analysts covering Signal Genetics (NASDAQ:SGNL), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Signal Genetics has been the topic of 3 analyst reports since September 23, 2015 according to StockzIntelligence Inc. The rating was initiated by H.C. Wainwright on Friday, January 8 with “Buy”. Rodman & Renshaw initiated Signal Genetics Inc (NASDAQ:SGNL) rating on Friday, January 8. Rodman & Renshaw has “Buy” rating and $4.0 price target. The company was maintained on Wednesday, September 23 by Chardan Capital Markets.

According to Zacks Investment Research, “Signal Genetics, Inc. is an emerging commercial stage, molecular diagnostic company. It is focused on providing diagnostic services that help physicians in decision making for the care of cancer patients. The Company’s flagship diagnostic service is the Myeloma Prognostic Risk Signature, or MyPRS (TM). Signal Genetics, Inc. is headquartered in New York.”

Insitutional Activity: The institutional sentiment decreased to 0.57 in Q2 2016. Its down 0.14, from 0.71 in 2016Q1. The ratio worsened, as 4 funds sold all Signal Genetics Inc shares owned while 3 reduced positions. 4 funds bought stakes while 0 increased positions. They now own 715,503 shares or 8.06% less from 778,231 shares in 2016Q1.
Perkins Cap Mgmt, a Minnesota-based fund reported 70,550 shares. Creative Planning holds 0% or 13,165 shares in its portfolio. Vanguard Group Inc Inc holds 102,575 shares or 0% of its portfolio. Financial Bank Of America De holds 0% or 18 shares in its portfolio. Moreover, Invsts Advisory Svcs has 0% invested in Signal Genetics Inc (NASDAQ:SGNL) for 39,250 shares. Susquehanna Intll Llp has 27,003 shares for 0% of their US portfolio. Hightower Ltd Company accumulated 0% or 411,614 shares. Renaissance Tech Ltd Liability Corp has 15,200 shares for 0% of their US portfolio. Citadel Advisors Ltd accumulated 34,787 shares or 0% of the stock. Blackrock Fund Advisors owns 1,341 shares or 0% of their US portfolio.

More recent Signal Genetics Inc (NASDAQ:SGNL) news were published by: Businesswire.com which released: “miRagen Therapeutics and Signal Genetics Sign Merger Agreement” on November 01, 2016. Also Marketwatch.com published the news titled: “Signal Genetics Inc.” on June 14, 2014. Globenewswire.com‘s news article titled: “Signal Genetics Appoints Tamara A. Seymour New Chief Financial Officer” with publication date: July 22, 2014 was also an interesting one.

SGNL Company Profile

Signal Genetics, Inc., incorporated on December 8, 2010, is a commercial stage, molecular genetic diagnostic company. The Firm is focused on providing diagnostic services that help physicians to make decisions concerning the care of cancer patients. The Company’s diagnostic service is the Myeloma Prognostic Risk Signature (MyPRS) test. The MyPRS test is a microarray gene expression profile (GEP), assay that measures the expression level of specific genes and groups of genes that are designed to predict an individual’s long-term clinical outcome/prognosis, giving a basis for personalized treatment options.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment